Clinical Trial Update: Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) [Phase 2]

View source ↗

Summary

Phase 2 trial of fosaprepitant (MK-0517, EMEND IV) in salvage treatment for chemotherapy-induced nausea and vomiting was terminated; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• EMEND (aprepitant)
• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Nausea, Vomiting | Phase 2 | Status: TERMINATED | Results posted: 2014-10-29